Ken Griffin Albireo Pharma, Inc. Call Options Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2022

Feb 14, 2023
SELL
$18.01 - $23.78 $111,662 - $147,436
-6,200 Reduced 19.56%
25,500 $551,000
Q3 2022

Nov 14, 2022
BUY
$16.32 - $26.37 $115,872 - $187,227
7,100 Added 28.86%
31,700 $614,000

Others Institutions Holding ALBO

# of Institutions
4
Shares Held
865
Call Options Held
0
Put Options Held
0
View Full List

About ALBIREO PHARMA, INC.

ALBO Quotes by TradingView
  • Ticker ALBO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 19,612,500
  • Description
  • Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as we...
More about ALBO
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email